Altshuler Ellery, Aryan Mahmoud, Kallumkal Govind, Gao Hanzhi, Wilson Jake, Ouni Ahmed, De Leo Edward, Hanayneh Wissam, Pan Kelsey
Department of Internal Medicine, University of Florida College of Medicine, Gainesville, FL, USA.
Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Hepat Oncol. 2022 May 24;9(2):HEP43. doi: 10.2217/hep-2021-0010. eCollection 2022 Apr.
β-blockers (BBs) have shown promise in improving overall survival (OS) in patients with breast, ovarian, pancreatic and lung cancer. However, few studies have evaluated the impact of BBs on unresectable hepatocellular carcinoma (HCC).
The authors compared clinical data and outcomes between unresectable HCC patients based on whether they were prescribed BBs.
There was significantly decreased disease progression in the BB group compared with the non-BB group (22.8 vs 28.0%; p < 0.05). No difference was seen in OS or progression-free survival between groups. Those specifically on selective BBs had improved OS (hazard ratio: 0.75; 95% CI: 0.61-0.94; p = 0.01) and progression-free survival (hazard ratio: 0.66; 95% CI: 0.45-0.96; p = 0.03) compared with non-BB patients.
Although the authors' study did not demonstrate that BBs improve OS in HCC, it did show decreased disease progression among patients with HCC who were taking BBs compared with those who were not.
β受体阻滞剂（BBs）已显示出有望改善乳腺癌、卵巢癌、胰腺癌和肺癌患者的总生存期（OS）。然而，很少有研究评估BBs对不可切除肝细胞癌（HCC）的影响。
作者比较了根据是否开具BBs的不可切除HCC患者的临床数据和结局。
与非BB组相比，BB组的疾病进展显著降低（22.8%对28.0%；p<0.05）。两组之间的总生存期或无进展生存期无差异。与非BB患者相比，那些专门使用选择性BBs的患者的总生存期（风险比：0.75；95%置信区间：0.61-0.94；p=0.01）和无进展生存期（风险比：0.66；95%置信区间：0.45-0.96；p=0.03）有所改善。
虽然作者的研究没有证明BBs能改善HCC患者的总生存期，但确实表明与未服用BBs的HCC患者相比，服用BBs的患者疾病进展有所降低。
